This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Breast Cancer Awareness Month: One Woman's Story Underscores Importance Of Understanding Risk

ROGERS, Ark., Oct. 1, 2013 /PRNewswire/ -- At age 44, Cyndi Pierre believed that her family history of breast cancer – her mother and sister were both diagnosed – put her at risk for developing the disease, too. She ate healthy, exercised, and saw her doctor regularly for mammograms, which were normal. Pierre even tested negative for the BRCA "breast cancer" gene but, knowing that almost 80% of breast cancer cases are sporadic and involve little to no family history of the disease, she wanted to learn more.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/63646-phenogen-sciences-breast-cancer-awareness-brevagen-cyndi-pierre-experience

"I thought I had covered all my bases, but I couldn't shake this nagging feeling," Pierre said. "So I took the next step with the BREVAGen test. The results made it possible for me to get insurance coverage for a 3-D MRI, and I discovered I already had cancer. I feel that test saved my life."

In recognition of Breast Cancer Awareness Month, Phenogen Sciences Inc., a wholly owned subsidiary of Genetic Technologies Group (NASDAQ: GENE) and makers of the BREVAGen breast cancer predictive risk assessment test, congratulates Pierre for stepping forward as the first patient to acknowledge BREVAGen's role in saving her life from breast cancer. Clinically validated, BREVAGen is the latest advance in assessing a woman's unique risk of developing non-familial or sporadic breast cancer. To honor Pierre, the company has made a contribution to her fundraising efforts for the 31 st Susan G. Komen 3-Day for the Cure® 60-mile walk.

Pierre's story is one of determination and collaboration. After talking with her care team about doing everything she could to prevent breast cancer, Pierre's nurse practitioner suggested BREVAGen—a noninvasive DNA test that analyzes a woman's genetic and clinical risk factors to determine her risk of breast cancer. BREVAGen showed Pierre's risk was 33 percent—nearly three times higher than the average woman's. Cyndi's high score prompted her insurance company to approve a more sensitive 3-D MRI, which would give doctors a more detailed look at her breast health. That test detected a small lump in her left breast. It was cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs